company background image
ASP

Acerus Pharmaceuticals TSX:ASP Stock Report

Last Price

CA$2.25

Market Cap

CA$17.3m

7D

-27.4%

1Y

-71.9%

Updated

26 Jun, 2022

Data

Company Financials
ASP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ASP Stock Overview

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health.

Acerus Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acerus Pharmaceuticals
Historical stock prices
Current Share PriceCA$2.25
52 Week HighCA$11.00
52 Week LowCA$2.25
Beta1.09
1 Month Change-43.04%
3 Month Change-75.00%
1 Year Change-71.88%
3 Year Change-89.77%
5 Year Change-91.00%
Change since IPO-99.49%

Recent News & Updates

Shareholder Returns

ASPCA PharmaceuticalsCA Market
7D-27.4%-0.3%0.3%
1Y-71.9%-70.9%-4.0%

Return vs Industry: ASP matched the Canadian Pharmaceuticals industry which returned -70.9% over the past year.

Return vs Market: ASP underperformed the Canadian Market which returned -4% over the past year.

Price Volatility

Is ASP's price volatile compared to industry and market?
ASP volatility
ASP Average Weekly Movement20.9%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement10.0%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: ASP is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 21% a week.

Volatility Over Time: ASP's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
200814Ed Gudaitishttps://www.aceruspharma.com

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men’s and women’s health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis.

Acerus Pharmaceuticals Fundamentals Summary

How do Acerus Pharmaceuticals's earnings and revenue compare to its market cap?
ASP fundamental statistics
Market CapUS$13.43m
Earnings (TTM)-US$27.94m
Revenue (TTM)n/a

-3.7x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ASP income statement (TTM)
Revenue-US$3.58m
Cost of RevenueUS$1.18m
Gross Profit-US$4.76m
Other ExpensesUS$23.18m
Earnings-US$27.94m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.63
Gross Margin132.86%
Net Profit Margin779.39%
Debt/Equity Ratio-758.7%

How did ASP perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ASP undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ASP?

Other financial metrics that can be useful for relative valuation.

ASP key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue-12.3x
Enterprise Value/EBITDA-1.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does ASP's PB Ratio compare to its peers?

ASP PB Ratio vs Peers
The above table shows the PB ratio for ASP vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average3.8x
COOL Core One Labs
2.6xn/aCA$11.3m
PILL Canntab Therapeutics
10.3xn/aCA$10.9m
LABS MediPharm Labs
0.3x37.2%CA$20.7m
FUZN High Fusion
2xn/aCA$3.7m
ASP Acerus Pharmaceuticals
n/an/aCA$17.3m

Price-To-Book vs Peers: ASP is good value based on its Price-To-Book Ratio (-2.9x) compared to the peer average (3.8x).


Price to Earnings Ratio vs Industry

How does ASP's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Book vs Industry: ASP is good value based on its Price-To-Book Ratio (-2.9x) compared to the Canadian Pharmaceuticals industry average (1.1x)


Price to Book Ratio vs Fair Ratio

What is ASP's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ASP PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ASP's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ASP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ASP's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ASP's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ASP's PEG Ratio to determine if it is good value.


Discover undervalued companies

  • Take a look at our analysis of ASP's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Acerus Pharmaceuticals regulatory filings.

Future Growth

How is Acerus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


72.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acerus Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of ASP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Acerus Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Acerus Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-31.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ASP is currently unprofitable.

Growing Profit Margin: ASP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ASP is unprofitable, and losses have increased over the past 5 years at a rate of 31.5% per year.

Accelerating Growth: Unable to compare ASP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ASP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).


Return on Equity

High ROE: ASP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is Acerus Pharmaceuticals's financial position?

Financial Health Score

0/6

Financial Health Score 0/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: ASP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: ASP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ASP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ASP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 50.4% each year


Discover healthy companies

Dividend

What is Acerus Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ASP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ASP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ASP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ASP's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ASP has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Ed Gudaitis

4.08yrs

Tenure

US$807,086

Compensation

Mr. Edward Gudaitis, also known as Ed, is President, Director and Chief Executive Officer at Acerus Pharmaceuticals Corp. since May 01, 2018. He is a Director for BioteCanada. Mr. Gudaitis has spent many y...


CEO Compensation Analysis

Compensation vs Market: Ed's total compensation ($USD807.09K) is above average for companies of similar size in the Canadian market ($USD175.18K).

Compensation vs Earnings: Ed's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ASP's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: ASP's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ASP insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Acerus Pharmaceuticals Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Acerus Pharmaceuticals Corporation
  • Ticker: ASP
  • Exchange: TSX
  • Founded: 2008
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$17.342m
  • Shares outstanding: 7.71m
  • Website: https://www.aceruspharma.com

Number of Employees


Location

  • Acerus Pharmaceuticals Corporation
  • 7025 Langer Drive
  • Suite 205
  • Mississauga
  • Ontario
  • L5N 0E8
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.